

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Fire Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Exandria. VA 22313-1450, on:

Date: 11/15/05

зу:____*УППП ДИ*С____

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: DAVIDSON, ROBERT S. ET AL.

10/706,810

EXAMINER: PAGE, THURMAN K.

APPLICATION No.:

ART UNIT:

1615

FILED:

NOVEMBER 12, 2003

CONF. No: 6949

FOR: METHOD AND APPARATUS FOR

MINIMIZING HEAT, MOISTURE, AND SHEAR DAMAGE TO MEDICANTS AND OTHER COMPOSITIONS DURING INCORPORATION

OF SAME WITH EDIBLE FILMS

Supplemental Information Disclosure Statement
Within Three Months of Application Filing or
Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

\boxtimes	Copies of	the	following	references	are enc	losed
-------------	-----------	-----	-----------	------------	---------	-------

cited	references
	cited

☐ References marked by asterisks

☐ The following:

U	No.	s of the following references can be found in parent U.S. Application :				
		All cited references References marked by asterisks The following:				
⊠	paten	application was filed after 30 June 2003 and no copies of U.S. ts nor published applications are enclosed (See Notice of Deputynissioner Kunin on 11 July 2003).				
	The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.					
		All cited references References marked by ampersands The following:				
Effect	of Info	rmation Disclosure Statement (37 C.F.R. § 1.97(h))				
that: exam result cited applic art to	(i) a (ination) s and to information the sultant do	tion Disclosure Statement is not to be construed as a representation search has been made; (ii) additional information material to the of this application does not exist; (iii) the information, protocols, the like reported by third parties are accurate or enabling; or (iv) the ation is, or is considered to be, material to patentability. In addition, es not admit that any enclosed item of information constitutes prior eject invention and specifically reserves the right to demonstrate that erence is not prior art.				
Fee F	aymer	<u>t</u>				
		believed due because this Information Disclosure Statement is being he mailing date of the first Office Action.				
	Applio certific	cant further submits that no fee is due in light of the following cation under 37 C.F.R. § 1.97(e) (check only one):				
		In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or				

3.

4.

In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP


Date: Nov 15 2005

Joseph P. Hamilton Registration No. 51,770

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208

Phone: (310) 788-9900 Fax: (310) 788-3399



					J.S. PATENT DOCUMENTS			
Examiner Initials*	Cito	е		ation d Code known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines Where Relevant Passage Relevant Figures Appea	s or
								· ·
				FOF	REIGN PATENT DOCUMENTS			
Examiner Initials*	Foreign Patent or Application er Cite Kind Code		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т		
	ВА	wo	02/02126		INNOVATA BIOMED LIMITÉD	01/10/2002		
								<u> </u>
								-
		<u> </u>	OTHER P	RIOR AR	T-NON PATENT LITERATURE D	OCUMENTS		J <u></u>
Examiner Initials*	Cite No.	(b	Include name o	f the author	(in CAPITAL LETTERS), title of the article symposium, catalog, etc.), date, page(s), and/or country where published.	(when appropriate)		Т
	BB	Ueshi retriev	ma, Yasuhide /ed from STN	e et al., "S , Databa	P-002346984, Chemical Abstra Saccharides for the Treatment se Accession No. 132:146641 uary 2000, 2 pages.	of Respiratory	Tract Diseases,"	
	вс				/ol. 015, No. 398 (C-0874), 9 ((), 16 July 1991 (Abstract).	October 1991,	and JP 03164139A	
							<u> </u>	\vdash
	L	<u></u>		 				<u>L</u>

EXAMINER		DATE CONSIDERED				
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not					
	considered. Include copy of this form with next communication to application(s).					